Pfizer paid $190 million to settle a class-action lawsuit claiming it violated federal antitrust laws by delaying generic versions of its Neurontin epilepsy drug, causing consumers to pay inflated prices for the drug. The lawsuit alleged that Pfizer delayed competition by improperly listing certain patents with the Food and Drug Administration, engaging in illegal promotion and sales of Neurontin for unapproved uses, filing and maintaining sham litigation with respect to certain patents, and making misrepresentations to the patent courts. The settlement covers consumers who purchased Neurontin from December 2002 to August 2008.